LDK-378


CAS No. : 1032900-25-6

LDK-378,1032900-25-6
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000197
Synonyms:5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
Molecular Formula:C₂₈H₃₆ClN₅O₃S
Molecular Weight:558.14
Target:ALK
IC50:0.2 nM [1]
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh

Assay:≥98%
Appearance:A crystalline solid
Cat No:I000197
Cas No:1032900-25-6
Product-Name:LDK-378
InChI:InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)
InChIKey:VERWOWGGCGHDQE-UHFFFAOYSA-N
SMILES:CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl

LDK378(Ceritinib) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively.
IC50 Value: 0.2 nM [1]
Target: ALK
in vitro: LDK378 shows great anti-proliferative activity in Ba/F3-NPM-ALK and Karpas290 cells with IC50 of 26.0 nM and 22.8 nM, compared with IC50 of 319.5 nM and 2477 nM in Ba/F3-Tel-InsR and Ba/F3-WT cells [1].
in vivo: LDK378 is designed to reduce the possibility of forming reactive metabolites and shows undetectable levels of glutathione (GSH) adducts (<1%) in liver microsomes. LDK378 has relatively good metabolic stability, with moderate CYP3A4 (Midazolam substrate) inhibition and hERG inhibition. LDK378 exhibits low plasma clearance in animals (mouse, rat, dog and monkey) compared to liver blood flow, with the oral bioavailability of above 55% in mouse, rat, dog and monkey. LDK378 induces a dose-dependent growth inhibition and tumor regression in the Karpas299 and H2228 rat xenograft models, with no body-weight loss. LDK378 shows no impact on insulin levels or plasma glucose utilization in the mouse upon chronic dosing up to 100 mg/kg [1].


[1]. Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013, Jun 6.

Related Products
  • CAS No. :1097917-15-1
    Product Name:

    ASP-3026

    Cat No: I000408 View details
  • CAS No. :1380575-43-8
    Product Name:

    LDK378 dihydrochloride

    Cat No: I001469 View details
  • CAS No. :761436-81-1
    Product Name:

    ALK inhibitor 1

    Cat No: I004817 View details
  • CAS No. :1116235-97-2
    Product Name:

    GSK1838705A

    Cat No: I000454 View details